Core Viewpoint - Zhonghui Biotech-B (02627) has seen a stock increase of over 5%, currently trading at HKD 42.68, with a transaction volume of HKD 8.3148 million, following the announcement of the initiation of Phase I clinical trials for its quadrivalent and trivalent influenza virus subunit vaccines [1] Group 1 - The company has recently launched Phase I clinical trials for its quadrivalent influenza virus subunit vaccine (adjuvanted) and trivalent influenza virus subunit vaccine (adjuvanted) [1] - The quadrivalent influenza virus subunit vaccine is expected to receive clinical trial approval from the National Medical Products Administration of the People's Republic of China in July 2024, while the trivalent version is anticipated to receive approval in October 2024 [1] - The vaccines are specifically designed for individuals aged 65 and above, addressing the increased risk of severe illness and death from influenza in this age group due to natural declines in immune function [1] Group 2 - The addition of the MF59-like adjuvant enhances immune response and increases antibody titers, providing better protection for the elderly population [1] - The impact of influenza on older adults significantly affects health and increases economic burden, highlighting the importance of these vaccines [1]
港股异动 | 中慧生物-B(02627)涨超5% 三价、四价流感病毒亚单位疫苗进入Ⅰ期临床试验阶段